Previous 10 | Next 10 |
SPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective ...
PLx Pharma Inc. (PLXP) Q1 2021 Earnings Conference Call May 14, 2021 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Natasha Giordano - President and Chief Executive Officer Rita O’Connor - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond J...
PLx Pharma (PLXP): Q1 GAAP EPS of -$0.73 misses by $0.52.As of March 31, 2021, the Company had cash and cash equivalents of $84.4 million.Press Release For further details see: PLx Pharma EPS misses by $0.52
– VAZALORE 325 mg and 81 mg, the first-ever novel, liquid-filled aspirin capsules, gain FDA approval – – Company secured $71.4 million of gross proceeds in an underwritten public offering of common stock for the launch of VAZALORE – –...
SPARTA, N.J., May 03, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more ef...
PLx Pharma Inc. (NASDAQ:PLXP) traded today at a new 52-week high of $10.70. Approximately 634,000 shares have changed hands today, as compared to an average 30-day volume of 510,000 shares. Over the past year, PLx Pharma Inc. has traded in a range of $2.28 to $10.70 and is now at $10.32,...
Shares of PLx Pharma Inc. (NASDAQ:PLXP) traded today at $10.78, eclipsing its 52-week high. Approximately 634,000 shares have changed hands today, as compared to an average 30-day volume of 510,000 shares. PLx Pharma Inc is a specialty pharmaceutical company focused on its clinically-val...
Shares of PLx Pharma Inc. (NASDAQ:PLXP) traded today at $10.95, eclipsing its 52-week high. So far today approximately 634,000 shares have been exchanged, as compared to an average 30-day volume of 510,000 shares. PLx Pharma Inc. (NASDAQ:PLXP) is currently priced 16.0% above its average ...
The FDA feedback on an upcoming regulatory review and differing opinions on commercialization prospects of key therapies are some of the reasons for analysts to change their outlook on stocks today. Provention Bio sinks further as RBC downgrades it on FDA feedbackProvention Bio (PRVB) ha...
PLx Pharma Inc. (PLXP) Q4 2020 Earnings Conference Call March 12, 2021 08:30 ET Company Participants Lisa Wilson - Investor Relations Natasha Giordano - President and Chief Executive Officer Rita O’Connor - Chief Financial Officer Conference Call Participants Elliot Wilbur - Raymond Ja...
News, Short Squeeze, Breakout and More Instantly...
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE ® ,...
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to...
2023-04-11 06:00:00 ET 3 Tips for Finding Winning Penny Stocks in 2023 The potential for exponential growth has made penny stocks a favorite among investors seeking to capitalize on undervalued, up-and-coming companies. Penny stocks , typically defined as those trading below $5 per ...